Aflibercept for intravitreal injection: In neovascular age-related macular degeneration

Drugs and Aging

Volumn 29, Issue 10, 2012, Pages 839-846

  Frampton, James E ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; BINDING AFFINITY; CATARACT; CONJUNCTIVAL HEMORRHAGE; CYST; DRUG ACTIVITY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; DRY NOSE; ENDOPHTHALMITIS; EPISTAXIS; EYE PAIN; HUMAN; HYPERTROPHY; INTRAOCULAR PRESSURE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOSE POLYP; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; RHINORRHEA; SIDE EFFECT; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS;

ANIMALS; HUMANS; INTRAVITREAL INJECTIONS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; WET MACULAR DEGENERATION;

EID: 84874614309     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-012-0015-2     Document Type: Article

References (39)

1. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs. 2008;68(8):1029-36. (Pubitemid 351693673)
2. La Cour M, Kiilgaard JF, Nissen MH. Age-related macular degeneration: epidemiology and optimal treatment. Drugs Aging. 2002;19(2):101-33. (Pubitemid 34494034)
3. de Jong PTVM. Age-related macular degeneration. N Engl J Med. 2006;355:1474-85. (Pubitemid 44511562)
4. Bird AC, Bressler NM, Bressler SB, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol. 1995;39(5):367-74.
5. Stewart MW. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin Proc. 2012;87(1):77-88.
6. Waisbourd M, Loewenstein A, Goldstein M, et al. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging. 2007;24(8):643-62.
7. Takahashi H, Shibuya M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005;109(3):227-41. (Pubitemid 41337127)
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76. (Pubitemid 36749215)
9. Vinores SA. Pegaptanib in the treatment of wet, age-related macular degeneration. Int J Nanomed. 2006;1(3):263-8.
10. Blick SKA, Keating GM, Wagstaff AJ. Ranibizumab. Drugs. 2007;67(8):1199-206. (Pubitemid 46871027)
11. Frampton JE. Ranibizumab: in diabetic macular oedema. Drugs. 2012;72(4):509-23.
12. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;19(364):1897-908.
13. Kovach JL, Schwartz SG, Flynn HW Jr, et al. Anti-VEGF treatment strategies for wet AMD. J Ophthalmol. 2012;2012:786870. (Epub 2012 Feb 28).
14. Stewart MW, Grippon S, Kirkpatrick P. Aflibercept. Nat Rev Drug Discov. 2012;11(4):269-70.
15. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. (Epub 2012 Mar 23).
16. Papadopoulous N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-85.
17. Zhang F, Tang Z, Hou X, et al. VEGF-B is dispensible for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. PNAS. 2009;106(15):6152-7.
18. Rakic J-M, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2003;44:3186-93. (Pubitemid 36759791)
19. EYLEA™ (aflibercept) injection: US prescribing information. Tarrytown (NY); Regeneron Pharmaceuticals, Inc. http://www.regeneron.com/Eylea/ eylea-fpi.pdf. Accessed 2 Apr 2012.
20. Regeneron Pharmaceuticals, Inc. Regeneron and Bayer announce approval of EYLEA™ (aflibercept) injection for the treatment of wet age-related macular degeneration in Australia [media release]. 2012 Mar 8. http://investor.regeneron.com. Accessed 2 Apr 2012.
21. Holash J, Davis S, Papadopoulos N, et al. VEGF-trap: a VEGF blocker with potent antitumor effects. PNAS. 2002;99(17):11393-8. (Pubitemid 34920936)
22. Konner JDJ. Use of soluble recombinant decoy receptor vascular endothelial growth factor trap (VEGF trap) to inhibit vascular endothelial growth factor activity. Clin Colorectal Cancer. 2004;4(Suppl. 2):S81-5.
23. Application number: 125387Orig1s000. Pharmacology review(s). http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/125387Orig1s000PharmR. pdf. Accessed 4 Apr 2012.
24. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology. 2011;118(6):1089-97.
25. Rudge JS, Holash J, Hylton D, et al. VEGF trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. PNAS. 2007;104(47):18363-70. (Pubitemid 350210713)
26. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006;90:1542-7. (Pubitemid 44862578)
27. Wiegand SJ, Zimmer E, Nork TM, et al. VEGF trap both prevents experimental choroidal neovascularization and causes regression of established lesions in non-human primates. Invest Ophthalmol Vis Sci. 2005; 46: E-abstract 1411-B180. http://abstracts.iovs.org/cgi/content/abstract/46/5/1411. Accessed 4 Apr 2012.
28. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-trap (R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195(2):241-8. (Pubitemid 36384298)
29. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor trap-eye in patients with neovascular age-related macular degeneration. Ophthalmology. 2009;116(11):2141-8.e1.
30. Application number: 125387Orig1s000. Clinical pharmacology and biopharmaceutics review(s). http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2011/125387Orig1s000ClinPharmR.pdf. Accessed 4 Apr 2012.
31. Regeneron. Vascular endothelial growth factor (VEGF) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW 1) [ClinicalTrials.gov identifier NCT00509795]. US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/ NCT00509795. Accessed 2 Apr 2012.
32. Bayer. Vascular endothelial growth factor (VEGF) trap-eye: investigation of efficacy and safety in wet age-related macular degeneration (AMD) (VIEW 2) [ClinicalTrials.gov identifier NCT00637377]. US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00637377. Accessed 2 Apr 2012.
33. Regeneron Pharmaceuticals, Inc. Bayer and Regeneron report positive top-line results of two phase 3 studies with VEGF Trap-EYE in wet age-related macular degeneration [media release]. http://investor.regeneron.com. Accessed 22 Nov 2010.
34. Nguyen QD, Heier J, Brown D, et al. Randomized, double-masked, active-controlled phase 3 trial of the efficacy and safety of intravitreal VEGF-Trap-Eye in wet AMD: one-year results of the VIEW-1 study [abstract no. 3073]. 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology; 2011 May 1-5; Fort Lauderdale (FL).
35. Schmidt-Erfurth U, Chong V, Kirchhof B, et al. Primary results of an international phase III study using intravitreal VEGF Trap-Eye compared to ranibizumab in patients with wet AMD (VIEW 2) [abstract no. 1650]. 2011 Annual Meeting of the Association for Research in Vision and Ophthalmology; 2011 May 1-5; Fort Lauderdale (FL).
36. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology. 2011;118(6):1098-106.
37. Regeneron Pharmaceuticals, Inc. Two year results of phase 3 studies with EYLEA™ (aflibercept) injection in wet AMD show sustained improvement in visual acuity [media release]. http://investor.regeneron.com. Accessed 5 Dec 2011.
38. Application number: 125387Orig1s000. Medical review(s). http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/125387Orig1s000MedR.pdf. Accessed 4 Apr 2012.
39. European Medicines Agency, Committee for Medicinal Products for Human Use. Summary of opinion (initial authorization): Eylea (aflibercept). http://www.ema.europa.eu/docs/en-GB/document-library/Summary-of-opinion--- Initial-authorisation/human/002392/WC500132884.pdf. Accessed 28 Sep 2012.